Citadel Advisors’s Lantern Pharma LTRN Stock Holding History

Citadel Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-32,895	Closed	-$99.7K	–	13688
2025 Q4	$99.7K	Buy	+32,895	New	+$122K	﹤0.01%	11647
2025 Q1	–	Sell	-37,587	Closed	-$156K	–	15131
2024 Q4	$120K	Buy	37,587 +35,434	+1,646%	+$121K	﹤0.01%	11189
2024 Q3	$7.9K	Buy	+2,153	New	+$8.87K	﹤0.01%	13334
2024 Q1	–	Sell	-24,858	Closed	-$133K	–	15108
2023 Q4	$106K	Sell	24,858 -5,774	-19%	-$20.4K	﹤0.01%	10855
2023 Q3	$104K	Buy	30,632 +5,895	+24%	+$26.8K	﹤0.01%	10841
2023 Q2	$140K	Buy	24,737 +13,761	+125%	+$71.1K	﹤0.01%	10433
2023 Q1	$53K	Sell	10,976 -8,345	-43%	-$43.8K	﹤0.01%	12080
2022 Q4	$117K	Buy	19,321 +6,568	+52%	+$32.9K	﹤0.01%	11004
2022 Q3	$61K	Buy	+12,753	New	+$68.6K	﹤0.01%	11489
2022 Q1	–	Sell	-11,095	Closed	-$89K	–	14172
2021 Q4	$89K	Buy	+11,095	New	+$101K	﹤0.01%	12829
2021 Q2	–	Sell	-11,192	Closed	-$203K	–	14085
2021 Q1	$203K	Buy	+11,192	New	+$196K	﹤0.01%	11667

Other funds holding LTRN

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors's LTRN Position: Q1 2026 in Review

Citadel Advisors sold out of Lantern Pharma (LTRN) in Q1 2026, closing a stake of 32,895 shares — an estimated $99.7K sold.

Citadel Advisors first reported a position in LTRN in Q1 2021 and held it in 11 quarters. The position peaked at $203K in Q1 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

Citadel Advisors reported no remaining Lantern Pharma position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 32,895 Lantern Pharma shares in Q1 2026, an estimated $99.7K.
Citadel Advisors first reported a position in Lantern Pharma in Q1 2021 and held it in 11 quarters.
Citadel Advisors's Lantern Pharma position peaked at $203K in Q1 2021.
33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.